Editorial
Innovation in diabetes: insulin, research priorities and new recruitment
First published: 13 November 2019
No abstract is available for this article.
References
- 1Beran D, Hirsch IB, Yudkin JS. What is innovation in the area of medicines? The example of insulin and diabetes. Diabet Med 2019; 36: 1526–1527.
- 2Baeres FMM, Gundgaard J, Brown-Frandsen K. What is innovation in the area of medicines? The example of insulin and diabetes. Diabet Med 2019; 36: 1528–1529.
- 3Turner B. Innovations in diabetes: what impact have they had on people with diabetes? Diabet Med 2019; 36: 1530–1531.
- 4Wylie TAF, Shah C, Connor R, Farmer AJ, Ismail K, Millar B et al. Transforming mental well-being for people with diabetes: research recommendations from Diabetes UK's 2019 Diabetes and Mental Well-Being Workshop. Diabet Med 2019; 36: 1532–1538.
- 5 Call for proposals: diabetes and eating disorders. Available at https://www.diabetes.org.uk/resources-s3/2019-07/Strategic%20Call%20for%20proposals_final.pdf. Last accessed 25 October 2019.
- 6Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541–551.
- 7Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 2019; 7: 344–355.
- 8Hopkins MD, Taylor R, Lean MEJ. The DiRECT principles: giving Type 2 diabetes remission programmes the best chance of success. Diabet Med 2019; 36: 1703–1704.
- 9Higgins KS, Scott EM. The recruitment crisis in diabetes and endocrinology. Diabet Med 2005; 22: 9–14.
